tbuckley/cabot-search huggingface dataset:
SP0041 Gout-The Coming Epidemic. The Impact on The Health Care System and The Society
Authors: L.T. Jacobsson
Journal: Annals of the Rheumatic Diseases (2016)

Gout is worldwide the most common non-degenerative inflammatory joint disease, exemplified by a prevalence of 3.9% in the US and 1.7–2.5% in Europe. The incidence increase with increasing age and BMI, is influenced by genetic, dietary factors and other life style factors as well the occurrence of comorbidity. Of the latter decreasing kidney function is by far the most important. Several studies have pointed out that the age-adjusted incidence is rising worldwide, partly due to an increase in age and BMI, and we therefore face an upcoming epidemic. Comorbidity outcomes: Gout identified in registers, thus reflecting the whole spectrum of the disease, has repeatedly been shown to be strongly associated with an increased morbidity in cardiovascular outcomes, deteriorating kidney function and overall mortality. To what extent this is related to hyperurecemia or systemic inflammation as reflected by clinical gout has not been completely disentangled. Very low serum-urate levels have on the other hand been suggested to increase the risk for dementia and Parkinsons disease, although this would need be confirmed. Health related Quality of Life (HQoL): Whereas it is clinically obvious that very severe gout can have severe impact on HQoL, there is limited data to what extent early disease or more limited gout manifestations reduces HQoL Societal costs: Once considered a disease of the wealthy, gout has recently been shown to be associated with lower income and socioeconomic class as is the case for most chronic diseases. It is difficult to disentangle the effects of joint manifestations and associated comorbidities on the incremental costs that some studies have demonstrated in groups of gout and this would need to be furthers studied. What can we do to stop this epidemic? Apparently there are still large opportunities for improvements with regard to early detection and initiation of urate lowering therapy. In addition, improvements in life style are likely to be highly protective. Since gout is an increasing problem, there is also a high need for studies describing the effects on HQoL and costs over the whole range of the disease. <h3>Disclosure of Interest</h3> None declared
Risk Factor Analysis for Thrombotic Microangiopathy after Reduced Intensity or Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Hirohisa Nakamae, Takahisa Yamane, Hagihara Kiyoyuki, Yasunobu Takeoka, Erina Sakamoto, Takahiko Nakane, Mika Nakamae, Ki-Ryang Koh, Kensuke Ohta, Masayuki Hino
Journal: Blood (2005)
Genomic Aberrations in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Count: Analysis of 1694 Patients.
Authors: Apostolia-Maria Tsimberidou, Peter McLaughlin, Susan O’Brien, Sijin Wen, William G. Wierda, John T. Manning, Lynne V. Abruzzo, Susan Lerner, Mark A. Hess, Hagop M. Kantarjian, Emil J. Freireich, Michael J. Keating
Journal: Blood (2006)
Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy
Authors: Li Liao, Bingzheng Shi, Heran Chang, Xiaoxia Su, Lichao Zhang, Chunsheng Bi, Yi Shuai, Xiaoyan Du, Zhihong Deng, Yan Jin
Journal: Theranostics (2016)

Systemic infusion of bone marrow-derived mesenchymal stem cells (BMSCs) has become a promising strategy for disease treatment and tissue regeneration. Strategies to enhance the efficiency of BMSC cell therapy are crucial to promote its clinical application. Here, we aimed to improve BMSC cell therapy by inhibiting the BMSC-induced coagulation reaction. Intravenous injection of gradient BMSCs into mice showed that BMSCs were not fully compatible with blood. Large doses of BMSCs induced a series of symptoms of respiratory failure and heart failure. Histological and homeostasis analysis confirmed that large doses of BMSCs induced disseminated intravascular thrombosis, exhaustion of platelets and coagulation factors, and prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT). Similar to mouse BMSCs, goat and human BMSCs also induced coagulation reactions in vitro and in vivo. The coagulation was induced mostly by tissue factor, the overexpression of which enhanced the procoagulant activity of BMSCs during in vitro culture. Notably, clinical doses of BMSCs in cell therapy also induced mild and reversible coagulation, which increased BMSC lung embolism and clearance. Anticoagulation treatment by heparin (400 U/kg) prevented BMSC-induced coagulation and the acute adverse effects of large-dose BMSCs infusion efficiently. Importantly, heparin treatment led to decreased BMSC lung embolism and enhanced migration and maintenance of BMSCs to target organs in cell therapy. Based on an experimental colitis model, we confirmed that heparin treatment enhanced the effect of BMSC therapy efficiently to reduce mortality, prevent weight loss, suppress inflammation reaction and alleviate tissue injury. In conclusion, BMSCs possess procoagulant activity that could induce disseminated coagulation and thrombosis in recipients. Anticoagulation treatment by heparin is a practical strategy to improve both the safety and therapeutic effect of BMSC therapy.
Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.
Authors: Marianne B. Treppendahl, Magnus Tobiasson, Anni Aggerholm, Mohsen Karimi, Trine Silkjaer, Lone S. Friis, Mette K. Andersen, Lars Kjeldsen, Mette S. Holm, Eva Hellström-Lindberg, Kirsten Grønbæk
Journal: Blood (2012)
AB0797 Ankle Fractures and Its Relationship between Osteoporosis, Diabetes and Obesity: Table 1
Authors: S. Rodríguez-Muguruza, A. Prior, A. Florido, J. Sanint, Y. García Mira, I. Casas, M. Martinez-Morillo, L. Mateo, J. Canellas, X. Tena, A. Olive, S. Holgado
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Osteoporosis is a major health problem worldwide and leads to several million fractures every year. Diabetes mellitus (DM) and obesity are an increasing threat for global health. While the pathophysiology of diabetic bone disease is unknown, some recent studies have demonstrated an increased fracture risk related to type 2 DM. Type 1 DM has also been associated with a decreased bone mineral density (BMD). <h3>Objectives</h3> To investigate the relationship between DM and obesity, and their relation to osteoporosis and ankle fractures. <h3>Methods</h3> Retrospective study 2008–2014. Center: tertiary academic hospital with a referral area of 850,000 inhabitants. The medical charts, dual-energy X-ray absorptiometry (DXA), radiographs and electronic data bases were retrospectively reviewed of patients seen for ankle fractures. Patients were classified in 4 groups: obesity (IMC&gt;30), non-obesity, diabetic and non-diabetic. We compared demographic data (age, gender), mechanism of injury (high or low energy trauma), pattern of fracture (single malleolus, bimaleollar and trimalleolar), treatment of the fracture, presence of new fracture (in other localizations) and osteoporosis treatment <h3>Results</h3> We compared a total of 65 diabetic patients (32.3% male and 67.7% female, mean age 61.8 years [DS 17.6]) with 234 non-diabetic patients (52.9% male, 47.1 female, mean age 31.5 [DS 41.7]) and 40 obese patients (37.5% male and 34.7% female, mean age 42 years [DS 21.2]) with 76 non obese patients (38.2% male, 61.8% female). The main characteristics of the study groups are presented in Table 1. There were no differences in fracture pattern, mechanism of injury, BMD and fracture treatment among all groups. Bimaleolar fracture was the most common pattern in all groups. Diabetic group had higher frequency of a low energy trauma, osteoporosis and new fracture. New fracture was reported in 12 patients, between 3 and 48 months (after the ankle fracture). There was 5 Colles9fracture, 3 hip, 2 in other localization. One patient had two fractures (Colles and vertebral) Obese group had higher frequency of osteopenia compared with non obese. <h3>Conclusions</h3> We did not found statistical differences between diabetic and obese compared with non diabetic or non obese patients. Ankle fracture in diabetic group could have features of osteoporotic injury including the high frequency of new fracture. <h3>Disclosure of Interest</h3> None declared
Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis
Authors: Johannes Schetelig, Liesbeth de Wreede, Michel van Gelder, Niels Smedegaard Andersen, Carol Moreno, Antonin Vitek, Michal Karas, Mauricette Michallet, Maciej J Machaczka, Martin Gramatzki, Dietrich Beelen, Jürgen Finke, Álvaro Urbano-Ispizúa, Liisa Volin, Jakob R. Passweg, Peter Dreger, Anja Henseler, Anja van Biezen, Martin Bornhäuser, Stefan Schoenland, Nicolaus Kröger
Journal: Blood (2015)
OP0174 The Development of The Modified DAS28-CRP To Improve Agreement with DAS28-ESR and Ensure Appropriate Disease Activity Stratification in RA
Authors: P.D.H. Hamann, K. Hyrich, A. Jobling, N. McHugh, G. Shaddick, J. Pauling
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Disease activity in rheumatoid arthritis (RA) has traditionally been measured using the 28-joint count disease activity score (DAS28) using ESR. Use of DAS28 with CRP in place of ESR is increasing. Evidence suggests these scores are not truly interchangeable and agreement varies dependant on disease activity. This study uses the BSRBR-RA to investigate agreement between these scores, proposing an optimised method to calculate the estimated DAS28-ESR using CRP (mDAS28-CRP) that offers higher interscore agreement than currently. <h3>Objectives</h3> To investigate and optimise agreement between the DAS28-ESR and DAS28-CRP scores using the BSRBR-RA. <h3>Methods</h3> Patients with concurrent measures of ESR and CRP were identified from the BSRBR-RA, enabling paired calculation of DAS28-ESR and DAS28-CRP using existing formulae. A non-linear regression model enabled prediction of ESR from CRP. Resulting values were used in the existing DAS28-ESR formula to calculate estimated disease activity (mDAS28-CRP). A Bayesian approach was used to acknowledge the uncertainty associated with the predictions and correctly propagate it through to mDAS28-CRP. Inference, including constructing credible intervals for predicted ESR and mDAS28-CRP, was performed using Markov-Chain-Monte-Carlo. Bland-Altman analysis and agreement matrices were used to compare agreement levels between mDAS28-CRP, DAS28-CRP and DAS28-ESR. <h3>Results</h3> 5457 patients (mean age 56 yrs, 76% female) with 31,084 data entries were identified where paired DAS28-ESR/DAS28-CRP scores could be calculated. Mean DAS28-ESR was 0.3 points greater than DAS28-CRP (4.4 (SD 1.7), 4.1 (SD 1.6) respectively) compared with mean mDAS28-CRP of 4.6 (SD 1.6; Fig 1). mDAS28-CRP had superior agreement with DAS28-ESR across remission, low and moderate disease activity, with only a 6.8% reduction in agreement at high disease activity when compared with the DAS28-CRP (Table 1). <h3>Conclusions</h3> The mDAS28-CRP (online calculator pending) allows calculation of a disease activity score, using the same component parts of the DAS28-CRP, and has higher agreement levels with the original validated DAS28-ESR, than the current DAS28-CRP in this cohort. Disease activity scores are fundamental in clinical trials and practice, forming a central role in guiding availability of therapeutic agents. It is therefore essential that scores used are both valid and, if used interchangeably, have high agreement levels. <h3>Disclosure of Interest</h3> None declared
P0037 : Progressive portal and lobular fibrosis in long term surviving pediatric liver grafts: Different compartments with different backgrounds
Authors: M. Baas, A.S. Gouw, M.C. van den Heuvel, H.J. Verkade, B.G. Hepkema, P.M. Peeters, R. Scheenstra
Journal: Journal of Hepatology (2015)
Peter John Leslie
Authors: Sarah Leslie
Journal: BMJ (2016)

Peter John Leslie had an infectious energy and enthusiasm for his work as a doctor as in so many other areas of life, and he inspired many. His loss has been felt keenly, not only among a wide circle of friends and family, but also at the Borders General Hospital, where he had been a prominent and highly respected clinician since 1992.

Born and brought up in Lisburn, near Belfast, Peter was fortunate to attend Friends’ School, where, unusually for the time, he was able to make friends with pupils and staff from across the sectarian divide. A very happy early childhood came to an end at the age of 11, owing to his father’s sudden and early death. After enduring a year at boarding school, which he hated, Peter became in effect the carer for his mother, whose mental and physical health was poor for the rest of her life. During his teens the “Troubles” were at their height, and, like so many of his generation and before—including his sister, Rhona, who emigrated to Canada—Peter left Northern Ireland, going on to study medicine at the University of Edinburgh.

Peter …
Leukemogenic Fusion Gene (p190 BCR-ABL) Transduction Into Hematopoietic Stem/Progenitor Cells In the Common Marmoset
Authors: Yamin Tian, Yan Dong, Seiichiro Kobayashi, Manabu Ozawa, Kiyoko Izawa, Yuansong Bai, Yasushi Soda, Erika Sasaki, Toshio Itoh, Naoki Oyaizu, Satoshi Takahashi, Arinobu Tojo, Chieko Kai, Kenzaburo Tani
Journal: Blood (2010)
Impact of the Presence of An Internal Tandem Duplicate of FlT3 Receptor (ITD) on the Outcome of Adult Patients with Acute Myelocytic Leukemia (AML) Autografted In First Remission (CR1)Norbert-Claude Gorin, Myriam Labopin, Jordi Esteve, and Mohamad Mohty, on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Authors: Norbert C. Gorin, Myriam Labopin, Jordi Esteve, Mohamad Mohty
Journal: Blood (2010)
LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.
Authors: Craig Reeder, Stephen M Ansell, Katherine Gano, Amylou C. Dueck, Christopher Conley, Grzegorz S. Nowakowski, Kelly Curtis, John Camoriano, Jose Leis, James L Slack, Riccardo Valdez, Rodger E. Tiedemann, Keith Stewart, Thomas E. Witzig
Journal: Blood (2012)
Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): A Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma
Authors: Jonathan R Fromm, Julie A. McEarchern, Dana Kennedy, Thomas Anju, Andrei R Shustov, Ajay K Gopal
Journal: Blood (2010)
The BCR-ABL Fusion Protein Sensitizes Acute Lymphoblastic Leukemia to Apoptotic Death Induced by the Dual Glycolytic and Glycosylation Inhibitor 2-Deoxy-D-Glucose.
Authors: Guy J Leclerc, Jianfeng Du, Joanna DeSalvo, Gilles M. Leclerc, Julio C. Barredo
Journal: Blood (2012)
PTH-044 The National Endoscopy Database (NED) Project
Authors: TJW Lee, L Macdougall, R Broughton, P Rogers, M Rutter
Journal: Gut (2016)

<h3>Introduction</h3> The UK National Endoscopy Database (NED) Project will enable prospective automatic data collection from endoscopy reporting systems in individual hospitals to a national database. Comprehensive national endoscopy data is vital for quality assurance, benchmarking, audit and research. Once fully deployed NED will accept 1 million procedures per year from over 300 hospitals. <h3>Methods</h3> The National Endoscopy Database is based on the successful JAG Endoscopy Training System (JETS). It has been developed to gather data for calculation of key performance indicators (KPIs) for OGD, flexible sigmoidoscopy, colonoscopy and ERCP. All the major endoscopy reporting system (ERS) manufacturers have engaged with the project and are modifying their systems to allow a mandatory minimum dataset to be automatically uploaded to a central database. The new data schema terms are based on MST 3.0 allowing mapping to a standardised terminology. <h3>Results</h3> Testing of the upload methodology has demonstrated it is secure, robust, scalable and accurate. To date, two of the major ERS manufacturers have implemented NED compatible software at designated pilot sites. Pilot testing is ongoing. Further roll out and pilot testing is planned over forthcoming months. <h3>Conclusion</h3> Initial results from the NED project demonstrate that the proposed upload methodology is reliable and accurate. Modifications to existing ERS are currently being performed by all major manufacturers and testing of uploading real time clinical data underway. The ability to centrally collect endoscopy performance data will be an invaluable tool for monitoring and improving endoscopy quality and will provide a platform for endoscopy research. <h3>Disclosure of Interest</h3> None Declared
A Bioinspired Ultraporous Nanofiber‐Hydrogel Mimic of the Cartilage Extracellular Matrix
Authors: Florian A. Formica, Ece Öztürk, Samuel C. Hess, Wendelin J. Stark, Katharina Maniura‐Weber, Markus Rottmar, Marcy Zenobi‐Wong
Journal: Advanced Healthcare Materials (2016)

A true biomimetic of the cartilage extracellular matrix (ECM) could greatly contribute to our ability to regenerate this tissue in a mechanically demanding, often inflamed environment. Articular cartilage is a composite tissue made of cells and fibrillar proteins embedded in a hydrophilic polymeric meshwork. Here, a polyanionic functionalized alginate is used to mimic the glycosaminoglycan component of the native ECM. To create the fibrillar component, cryoelectrospinning of poly(ε‐caprolactone) on a −78 °C mandrel, subsequently treated by O 2 plasma, is used to create a stable, ultraporous and hydrophillic nanofiber network. In this study, cell‐laden, fiber‐reinforced composite scaffolds thicker than 1.5 mm can be created by infiltrating a chondrocyte/alginate solution into the fiber mesh, which is then physically cross‐linked. The fibrillar component significantly reinforces the chondroinductive, but mechanically weak sulfated alginate hydrogels. This allows the production of a glycosaminoglycan‐ and collagen type II‐rich matrix by the chondrocytes as well as survival of the composite in vivo. To further enhance the system, the electrospun component is loaded with dexamethasone, which protected the cells from an IL‐1β‐mediated inflammatory insult.
High-Dose Methotrexate and Cytarabine Chemotherapy May Be Effective and Safe in Solid Organ Transplant Recipients with Primary CNS Lymphomas (PCNSL)
Authors: Laura Moise, Clemence Matta, Sylvain Pilorge, Marius Moldovan, Christophe Ferme, Antoine Durrbach, Vincent Ribrag
Journal: Blood (2008)
Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia
Authors: Niklas Gunnarsson, Martin Hoglund, Leif Stenke, Solveig Wallberg Jonsson, Fredrik Sandin, Magnus Bjorkholm, Arta Dreimane, Mats Lambe, Berit Markevarn, Ulla Olsson-Stromberg, Hans Wadenvik, Johan Richter, Anders Sjalander
Journal: Blood (2015)
Prolylcarboxypeptidase Murine Hypomorphs Are Hypertensive and Prothrombotic
Authors: Gregory N Adams, Yihua Zhou, Gretchen Larusch, Marvin T Nieman, Brian Hoit, Gretta Jacobs, Xin Yu, Fakhri Mahdi, Zia Shariat-Madar, Louis D’Alecy, Yoshio Okada, Alvin H. Schmaier
Journal: Blood (2008)
Cerebral Arterial Velocities in SCA-Children with Abnormal Doppler Are Reduced and Normalized More Frequently after Transplantation Than after Transfusion Program (French National Trial “Drepagreffe” AP-HP N°: NCT 01340404)
Authors: Francoise Bernaudin, Suzanne Verlhac, Regis Peffault Delatour, Jean-Hugues Dalle, Eleonore Petras, Valentine Brousse, Isabelle Thuret, Catherine Paillard, Benedicte Neven, Claire Galambrun, Maryse Etienne-Julian, Corinne Pondarre, Laurence Lutz, Corinne Guitton, Florence Missud, Camille Runel, Charlotte Jubert, Gisèle Elana, Monique Elmaleh, Cécile Arnaud, Annie Kamdem, Gérard Socié
Journal: Blood (2014)
Downregulation of SOX7 by DNA Methylation and Its Tumor Suppressing Role In Acute Myeloid Leukemia
Authors: Tsz-Kan Fung, Kin-Pong Fan, HaiXia Wan, Howard C.H. Chow, Anders S.Y. Wong, Tommas S.K. Wan, Yok Lam Kwong, Raymond Liang, Anskar Y.H. Leung
Journal: Blood (2010)
UK must act to stem brain drain of scientists, MPs say
Authors: Anne Gulland
Journal: BMJ (2016)

The government must prevent a “brain drain” of scientists from the United Kingdom by exempting them from any forthcoming tightening of rules on immigration to the UK, MPs have urged.

Their report on the effect on science and research of the UK’s decision to leave the European Union said that although planning for exit negotiations was still under way, “there is clear agreement that researcher mobility is a crucial component of the UK’s successful research science sector.”1 Evidence submitted to the House of Commons Science and Technology Committee’s inquiry showed that some researchers were “seriously considering” leaving the UK, and the report warned of the threat of a brain drain.

Ottoline Leyser from the Royal Society told MPs on the committee that the 31 000 scientists …
Reduced Intensity Conditioning Regimen for Allografting Following Autografting Has Strong Anti-Myeloma Activity and Delays Disease Progression Compared to Tandem Autografting.
Authors: A.M. Carella, E. Lerma, S. Nati, A. Congiu, E. Rossi, M. Spriano, R. Vimercati
Journal: Blood (2006)
P11.05 Whorling-sclerosing type of meningioma. CD34 and P53 IHC-positivity with lack of malignant features in a rare meningioma type
Authors: R. Sari, F. H. Bolukbasi, M. Onoz, O. Baskan, M. A. Altinoz, A. Sav, I. Elmaci
Journal: Neuro-Oncology (2016)
In the Presence of Pre-Existing Factor VIII (FVIII) Immunity, Hematopoietic Stem Cells (HSC) That Are Genetically Modified To Express FVIII in Platelets Were Successfully Transplanted into Hemophilic Mice under Myeloablative and Various Non-Myeloablative Conditions.
Authors: Qizhen Shi, Scot A. Fahs, David A. Wilcox, Erin L. Kuether, Hartmut Weiler, Robert R. Montgomery
Journal: Blood (2007)
Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma.
Authors: Francisco Hernandez-Ilizaliturri, Ping-Chiao Tsio, Ryan Campagna, Cory Marvis, Wasif Riaz, Elizabeth Gruber, John Gibbs, Myron S. Czuczman
Journal: Blood (2009)